1. Epigenetics
  2. Epigenetic Reader Domain
    Histone Methyltransferase


Cat. No.: HY-12856 Purity: 99.29%
Handling Instructions

GSK503 is a potent and specific inhibitor of EZH2 methyltransferase with Kiapp values of 3 to 27 nM.

For research use only. We do not sell to patients.
GSK503 Chemical Structure

GSK503 Chemical Structure

CAS No. : 1346572-63-1

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 125 In-stock
5 mg USD 108 In-stock
10 mg USD 156 In-stock
50 mg USD 540 In-stock
100 mg USD 960 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

    GSK503 purchased from MCE. Usage Cited in: Oncotarget. 2017 Apr 25;8(35):58654-58667.

    Treatment of RCC cells with an EZH2 inhibitor (GSK503) upregulates modulators of the Hippo pathway and SAV1 expression at the mRNA and protein levels.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    GSK503 is a potent and specific inhibitor of EZH2 methyltransferase with Kiapp values of 3 to 27 nM.

    IC50 & Target

    Ki: 3 to 27 nM (EZH2)[1]

    In Vitro

    GSK503 inhibits the methyltransferase activity of wild type and mutant EZH2 with similar potency (Kiapp=3-27 nM) and is structurally related to GSK126 and GSK343. GSK503 is >200 fold selective over EZH1 (Kiapp=636 nM) and >4000 fold selective over other histone methyltransferases[1].

    In Vivo

    In a melanoma mouse model, conditional EZH2 ablation as much as treatment with the GSK503 stabilizes the disease through inhibition of growth and virtually abolishes metastases formation without affecting normal melanocyte biology[2]. GSK503 displays favorable pharmacokinetics in mice. GSK503, but not vehicle, prevents the formation of germinal center after SRBC or NP-KLH immunization, phenocopying the Ezh2 null phenotype. GSK503 treatment leads to reduced numbers of GC B-cells by flow cytometry, reduces number and volume of GCs by immunohistochemistry, and impairs formation high affinity antibodies[1].

    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 1.8987 mL 9.4936 mL 18.9872 mL
    5 mM 0.3797 mL 1.8987 mL 3.7974 mL
    10 mM 0.1899 mL 0.9494 mL 1.8987 mL
    Please refer to the solubility information to select the appropriate solvent.
    Animal Administration

    Mice: To pharmacologically inhibit Ezh2 activity, Tyr::N-RasQ61K Ink4a-/- and C57Bl/6 mice are subjected to treatment with GSK503, which is diluted (15 mg/mL) in 20% Captisol solution. Efficient Ezh2 inhibition is achieved by daily intraperitoneal injections of 150 mg/kg GSK503 over 35 consecutive days. Mice are monitored during and after treatment to measure GSK503-induced reversible weight loss. C57Bl/6 and Foxn1nu/nu mice engrafted with melanoma cells are subjected to TM and GSK503 treatment as described above[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight




    CAS No.




    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 44 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.: